CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Summary: The definition of ischaemic stroke has been recently updated as an acute episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischaemia in the presence of a cerebral infarction. This “tissular” definition has highlighted the importance of pathophysiological processes underlying cerebral damage. In particular, post-ischaemic inflammation in the brain and in the blood stream could influence crucial steps of the tissue injury/repair cascade. CC and CXC chemokines orchestrate the inflammatory response in atherosclerotic plaque vulnerability and cerebral infarction. These molecules exert their activities through the binding to selective transmembrane receptors. CC and CXC chemokines modulate crucial processes (such as inflammatory cell recruitment and activation, neuronal survival, neoangio-genesis). On the other hand, CXC chemokines could also modulate stem cell homing, thus favouring tissue repair. Given this evidence, both CC and CXC chemokines could represent promising therapeutic targets in primary and secondary prevention of ischaemic stroke. Only preliminary studies have been performed investigating treatments with selective chemokine agonists/antagonists. In this review, we will update evidence on the role and the potential therapeutic strategies targeting CC and CXC chemokines in the pathophysiology of ischaemic stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0027 · Cited by 3,889
Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
Yusuf, S., Diener, H.-C., Sacco, R. L., Cotton, D., Ôunpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804593 · Cited by 785
Structure, Function, and Inhibition of Chemokines
Fernandez, E. J., & Lolis, E. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.091901.115838 · Cited by 609
Tuning inflammation and immunity by chemokine sequestration: decoys and more
Mantovani, A., Bonecchi, R., & Locati, M. (2006) · Nature Reviews Immunology · doi:10.1038/nri1964 · Cited by 481
Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
Kapadia, R. (2008) · Frontiers in Bioscience · doi:10.2741/2802 · Cited by 433
Absence of the Chemokine Receptor CCR2 Protects Against Cerebral Ischemia/Reperfusion Injury in Mice
Dimitrijevic, O. B., Stamatovic, S. M., Keep, R. F., & Andjelkovic, A. V. (2007) · Stroke · doi:10.1161/01.str.0000259709.16654.8f · Cited by 368
Inflammatory Cytokines in Acute Ischemic Stroke
Tuttolomondo, A., Di Raimondo, D., di Sciacca, R., Pinto, A., & Licata, G. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786848739 · Cited by 325
Schistosoma mansoni secretes a chemokine binding protein with antiinflammatory activity
Smith, P., Fallon, R. E., Mangan, N. E., Walsh, C. M., Saraiva, M., Sayers, J. R., McKenzie, A. N. J., Alcami, A., & Fallon, P. G. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050955 · Cited by 160
Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
Hickman, S. E., & Khoury, J. E. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791011982 · Cited by 120
Cited by
Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease
Newcombe, E. A., Camats-Perna, J., Silva, M. L., Valmas, N., Huat, T. J., & Medeiros, R. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1313-3 · Cited by 532
Inflammatory responses in hypoxic ischemic encephalopathy
Liu, F., & Mccullough, L. D. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.89 · Cited by 283
Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases
Bose, S., & Cho, J. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0161-z · Cited by 220
“It is conceivable that these small chemical compounds could have several modes of action: they may competitively bind to the same site of the receptor, alter the tertiary or the quaternary structure of the receptor protein or interfere with the receptor bioactivity (Mirabelli-Badenier et al. 2011).”
BackgroundInfluentialThe Role of Selected Pro-Inflammatory Cytokines in Pathogenesis of Ischemic Stroke
Pawluk, H., Woźniak, A., Grześk, G., Kołodziejska, R., Kozakiewicz, M., Kopkowska, E., Grzechowiak, E., & Kozera, G. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s233909 · Cited by 218
Systematic Review of the Neurobiological Relevance of Chemokines to Psychiatric Disorders
Stuart, M. J., Singhal, G., & Baune, B. T. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00357 · Cited by 163
Metadata
- Authors
- Viviani, G. L., Dallegri, F., Quercioli, A., Veneselli, E., Mach, F., Mirabelli-Badenier, M., Braunersreuther, V., & Montecucco, F.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2011
- Volume
- 105
- Issue
- 03
- Pages
- 409-420
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2028314455
- Cited by
- 144
- References
- 9
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.